Physician profile

Brad W Jones

Foot & Ankle Surgery · Springfield, MO

NPI 1053570903

$414.36

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Foot & Ankle Surgery

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$308.14

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Smith+Nephew, INC. $117.32 2019-2024 Collagenase Santyl
Averitas Pharma INC. $86.15 2023 Qutenza
Organogenesis INC. $83.18 2021-2024 Puraply
Stryker Corporation $34.38 2022
Kyowa Kirin, INC. $25.65 2024 Crysvita
Nevro Corp. $18.63 2022
Boston Scientific Corporation $17.46 2024 Wavewriter Alpha Prime 16
Novo Nordisk INC $17.19 2023 Ozempic, Rybelsus
Amgen INC. $14.40 2024 Krystexxa

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Brad W Jones

$414.36

in general payments reported 2019-2025

Years
2019-2024
Top company
Smith+Nephew, INC.

https://glasscript.com/doctor/820278/brad-w-jones

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.